- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT00064701
Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients
A Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Prograf (Tacrolimus)/MMF, Modified Release (MR) Tacrolimus/MMF and Neoral (Cyclosporine)/MMF in de Novo Kidney Transplant Recipients
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
This was a 3 arm randomized, open-label, comparative, multi-center study in de novo kidney transplant recipients at 60 centers in the U.S., Canada and Brazil.
The study consisted of a 1-year post-transplant efficacy and safety study with a clinical continuation phase of a minimum of 2 years or until commercial availability of tacrolimus modified release, unless the Data Safety Monitoring Board or sponsor specified otherwise.
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Porto Alegre, Brasilia, 90240-520
-
Rio de Janeiro, Brasilia, 21041-003
-
Sao Paulo, Brasilia, 04038-002
-
Sao Paulo, Brasilia, 04013-043
-
Sao Paulo, Brasilia, 05465-040
-
-
-
-
Alberta
-
Edmonton, Alberta, Kanada
-
-
British Columbia
-
Vancouver, British Columbia, Kanada
-
-
Ontario
-
Toronto, Ontario, Kanada
-
-
Quebec
-
Montreal, Quebec, Kanada
-
-
-
-
Alabama
-
Birmingham, Alabama, Yhdysvallat, 35294
-
Mobile, Alabama, Yhdysvallat, 36617
-
-
California
-
Loma Linda, California, Yhdysvallat, 92354
-
Los Angeles, California, Yhdysvallat, 90033
-
Los Angeles, California, Yhdysvallat, 90057
-
Los Angeles, California, Yhdysvallat, 90058
-
Los Angeles, California, Yhdysvallat, 90095-7306
-
Palo Alto, California, Yhdysvallat, 94304
-
San Diego, California, Yhdysvallat, 92103
-
San Diego, California, Yhdysvallat, 92123
-
San Francisco, California, Yhdysvallat, 94115
-
-
Colorado
-
Denver, Colorado, Yhdysvallat, 80262
-
-
District of Columbia
-
Washington, District of Columbia, Yhdysvallat, 20010
-
-
Florida
-
Gainesville, Florida, Yhdysvallat, 32610-0224
-
Jacksonville, Florida, Yhdysvallat, 32216
-
-
Georgia
-
Augusta, Georgia, Yhdysvallat, 30912
-
-
Illinois
-
Chicago, Illinois, Yhdysvallat, 60637
-
Chicago, Illinois, Yhdysvallat, 60612
-
-
Indiana
-
Indianapolis, Indiana, Yhdysvallat, 46202
-
-
Kentucky
-
Lexington, Kentucky, Yhdysvallat, 40536
-
-
Louisiana
-
New Orleans, Louisiana, Yhdysvallat, 70112
-
New Orleans, Louisiana, Yhdysvallat, 70121
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02214
-
-
Michigan
-
Ann Arbor, Michigan, Yhdysvallat, 48109-0364
-
Detroit, Michigan, Yhdysvallat, 48202
-
-
New Jersey
-
Livingston, New Jersey, Yhdysvallat, 07039
-
New Brunswick, New Jersey, Yhdysvallat, 08901
-
-
New York
-
Albany, New York, Yhdysvallat, 12208
-
Buffalo, New York, Yhdysvallat, 14203
-
New York, New York, Yhdysvallat, 10029
-
Valhalla, New York, Yhdysvallat, 10595
-
-
North Carolina
-
Chapel Hill, North Carolina, Yhdysvallat, 27599-7211
-
Durham, North Carolina, Yhdysvallat, 27710
-
-
Ohio
-
Cincinnati, Ohio, Yhdysvallat, 45267
-
-
Oregon
-
Portland, Oregon, Yhdysvallat, 97210
-
Portland, Oregon, Yhdysvallat, 97239-2940
-
-
Pennsylvania
-
Harrisburg, Pennsylvania, Yhdysvallat, 17104
-
Philadelphia, Pennsylvania, Yhdysvallat, 19104
-
Philadelphia, Pennsylvania, Yhdysvallat, 19107
-
-
Tennessee
-
Nashville, Tennessee, Yhdysvallat, 37212-4750
-
-
Texas
-
Dallas, Texas, Yhdysvallat, 75246
-
Dallas, Texas, Yhdysvallat, 75235
-
Houston, Texas, Yhdysvallat, 77030
-
San Antonio, Texas, Yhdysvallat, 78229-3900
-
-
Utah
-
Salt Lake City, Utah, Yhdysvallat, 84132
-
-
Virginia
-
Fairfax, Virginia, Yhdysvallat, 22031
-
-
Wisconsin
-
Madison, Wisconsin, Yhdysvallat, 53792-7375
-
Milwaukee, Wisconsin, Yhdysvallat, 53226
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Recipient of a primary or retransplanted non-human leukocyte antigen (HLA)-identical living or non-HLA-identical cadaveric kidney transplant
- Age greater or equal to 12 years
Exclusion Criteria:
- Recipient or donor is known seropositive for human immunodeficiency virus (HIV)
- Has current malignancy or history of malignancy
- Has significant liver disease
- Has uncontrolled concomitant infection or any other unstable medical condition
- Is receiving everolimus or enteric coated mycophenolic acid at any time during the study
- Received kidney with a cold ischemia time of equal or more than 36 hours
- Received kidney transplant from a cadaveric donor equal or more than 60 years of age
- Received intravenous immunoglobulin (IVIG) therapy prior to randomization
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: Tacrolimus
Participants received a first dose of tacrolimus between 0.075 and 0.10 mg/kg twice daily, orally prior to or within 48 hours of the completion of the transplant procedure, and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events.
Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
|
The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
Muut nimet:
Oral
Muut nimet:
|
Active Comparator: Tacrolimus Modified Release
Participants received a first dose of tacrolimus modified release between 0.15 and 0.20 mg/kg/day, given as a single oral dose in the morning, prior to or within 48 hours following the completion of the transplant procedure, and subsequently as once daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events.
Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
|
Oral
Muut nimet:
The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
Muut nimet:
|
Active Comparator: Cyclosporine
Participants received a first dose of cyclosporine between 4 to 5 mg/kg orally prior to or within 48 hours following the completion of the transplant procedure and subsequently as twice daily oral doses adjusted based on clinical evidence of efficacy, blood concentrations of tacrolimus and adverse events.
Participants also received 1.0 g mycophenolate mofetil orally twice daily throughout the study.
|
Oral
Muut nimet:
The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
Muut nimet:
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Percentage of Participants With Efficacy Failure
Aikaikkuna: one year
|
Efficacy failure is defined as any participant who died, experienced a graft failure (permanent return to dialysis [> 30 days] or retransplant), had a biopsy-confirmed (Banff Grade ≥ I) acute rejection (BCAR), or was lost to follow-up. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. |
one year
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Patient Survival at One Year
Aikaikkuna: One year
|
Patient survival is defined as any participant who is known to be alive one year after the skin closure date.
Participants who died or whose outcome was unknown at one year were considered to be non-survivors.
|
One year
|
Graft Survival at One Year
Aikaikkuna: One year
|
Graft survival defined as any participant who did not meet the criteria for graft loss, where graft loss is defined as any re-transplant, permanent return to dialysis (> 30 days), patient death, or participant whose outcome at one year was unknown. Participants were only counted once regardless of how many criteria were met. |
One year
|
Percentage of Participants With Biopsy Confirmed Acute Rejection at 6 and 12 Months
Aikaikkuna: Six months and 12 months
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. Acute rejection is defined as a grade ≥ I. |
Six months and 12 months
|
Time to First Biopsy-confirmed Acute Rejection Episode
Aikaikkuna: one year
|
Time to first biopsy-confirmed acute rejection episode defined as the number of days from skin closure (Day 0) to the date of biopsy. Rejection episodes were confirmed by biopsy by the clinical site pathologist and graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. Acute rejection is defined as a grade ≥ I. |
one year
|
Number of Participants Requiring Anti-lymphocyte Antibody Therapy for Treatment of Rejection
Aikaikkuna: one year
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Participants with histologically-proven Banff Grade II or III rejection or participants with steroid-resistant rejection were treated with anti-lymphocyte antibody treatment according to institutional practice. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade I: Significant interstitial infiltration and foci of moderate to severe tubulitis; Grade II: Mild to severe intimal arteritis Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. |
one year
|
Severity of Acute Rejection
Aikaikkuna: one year
|
Rejection episodes were confirmed by biopsy by the clinical site pathologist. Biopsies were graded according to the 1997 Banff criteria: Borderline: No intimal arteritis present but foci of mild tubulitis; Grade IA: Significant interstitial infiltration and foci of moderate tubulitis; Grade IB: Significant interstitial infiltration and foci of severe tubulitis; Grade IIA: Mild to moderate intimal arteritis in at least 1 arterial cross section Grade IIB: Severe intimal arteritis comprising >25% of the luminal area lost in at least 1 arterial cross section; Grade III: Transmural arteritis and/or arterial fibrinoid change and necrosis of medial smooth muscle cells with accompanying lymphocytic infiltrate in vessel. |
one year
|
Number of Participants Experiencing Multiple Rejection Episodes
Aikaikkuna: one year
|
This analysis includes rejection episodes that were either confirmed by biopsy by the clinical site pathologist or were clinically treated.
|
one year
|
Number of Participants With Clinically Treated Acute Rejection Episodes
Aikaikkuna: one year
|
A clinically treated acute rejection episode was any biopsy-confirmed or suspected rejection episode that was treated with immunosuppressive therapy.
|
one year
|
Number of Participants With Treatment Failure
Aikaikkuna: one year
|
Treatment failure was defined as the discontinuation of randomized study drug for any reason.
Participants who met the definition of treatment failure were to be followed throughout the 12-month treatment period.
|
one year
|
Number of Participants Who Crossed Over Due to Treatment Failure
Aikaikkuna: one year
|
Participants were allowed to cross over to an alternative primary immunosuppressive regimen (either to the tacrolimus or cyclosporine treatment arms) to address an adverse event which led to randomized study drug discontinuation or in the case of severe or refractory rejection.
Crossover to the modified release tacrolimus treatment arm was not permitted.
|
one year
|
Change From Month 1 in Serum Creatinine at Month 6 and Month 12
Aikaikkuna: Month 1, Month 6, and Month 12
|
Renal function was assessed by the change from Month 1 in serum creatinine six months and 12 months after transplant.
|
Month 1, Month 6, and Month 12
|
Change From Month 1 in Creatinine Clearance at Month 6 and Month 12
Aikaikkuna: Month 1, Month 6, and Month 12
|
Renal function was assessed by creatinine clearance, calculated using the Cockcroft-Gault formula.
|
Month 1, Month 6, and Month 12
|
Kaplan-Meier Estimate of Patient Survival at the End of the Study
Aikaikkuna: End of study (maximum time on study was 1,941 days).
|
Patient survival was defined as any participant who was alive at the end of the study.
Patient survival was censored at the time of last follow-up contact.
|
End of study (maximum time on study was 1,941 days).
|
Kaplan-Meier Estimate of Graft Survival at the End of the Study
Aikaikkuna: End of study (maximum time on study was 1,941 days).
|
Graft survival was defined as any participant who did not meet the definition of graft loss, where graft loss was any retransplant or the permanent return to dialysis (more than 30 days) or patient death. Graft survival was censored at the time of last follow-up contact. |
End of study (maximum time on study was 1,941 days).
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Arvio)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Arvio)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Huumeiden fysiologiset vaikutukset
- Farmakologisen vaikutuksen molekyylimekanismit
- Infektiota estävät aineet
- Entsyymin estäjät
- Reumaattiset aineet
- Antineoplastiset aineet
- Immunosuppressiiviset aineet
- Immunologiset tekijät
- Dermatologiset aineet
- Bakteerien vastaiset aineet
- Antibiootit, antineoplastiset
- Antifungaaliset aineet
- Tuberkulaariset aineet
- Antibiootit, antituberkulaariset
- Kalsineuriinin estäjät
- Takrolimuusi
- Mykofenolihappo
- Syklosporiini
- Syklosporiinit
Muut tutkimustunnusnumerot
- 02-0-158
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Munuaisensiirto
-
The Affiliated Hospital of Qingdao UniversityRekrytointiMunuaissolukarsinooma | Eturauhassyöpä | Virtsarakon syöpä | Virtsaputken kivi | Munuaiskivi | Peniksen syöpä | Lantion kasvain | Lisämunuaisen kasvain | Toimimaton munuainen | Munuaisten kysta | Ureteropelvic liitoksen tukos | Munuaislantion karsinooma | Virtsaputken kasvain | Duplex KidneyKiina
Kliiniset tutkimukset Tacrolimus
-
Astellas Pharma IncValmis
-
Chong Kun Dang PharmaceuticalValmisMunuaissiirtoKorean tasavalta
-
NovartisSandozValmisMunuaisensiirtoYhdysvallat
-
Chong Kun Dang PharmaceuticalTuntematonMunuaissiirtoKorean tasavalta
-
Novartis PharmaceuticalsValmisFarmakokinetiikkatutkimus de Novon munuaissiirrossaSaksa
-
Nantes University HospitalEi vielä rekrytointia
-
Glenmark Pharmaceuticals Ltd. IndiaValmis
-
Taro Pharmaceuticals USAValmis
-
Novartis PharmaceuticalsValmis
-
Hospital Universitario 12 de OctubreInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Fundación... ja muut yhteistyökumppanitValmisMEMBRAANINEN NEFROPATIAEspanja